147 related articles for article (PubMed ID: 18246351)
1. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Munkelt D; Koehl U; Kloess S; Zimmermann SY; Kalaäoui RE; Wehner S; Schwabe D; Lehrnbecher T; Schubert R; Kreuter J; Klingebiel T; Esser R
Cancer Chemother Pharmacol; 2008 Oct; 62(5):821-30. PubMed ID: 18246351
[TBL] [Abstract][Full Text] [Related]
2. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.
Styczynski J; Toporski J; Wysocki M; Debski R; Chybicka A; Boruczkowski D; Wachowiak J; Wojcik B; Kowalczyk J; Gil L; Balwierz W; Matysiak M; Krawczuk-Rybak M; Balcerska A; Sonta-Jakimczyk D
Anticancer Res; 2007; 27(3B):1547-51. PubMed ID: 17595774
[TBL] [Abstract][Full Text] [Related]
6. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative and immunosuppressive properties of treosulfan in mice.
Sjöö F; Hassan Z; Abedi-Valugerdi M; Griskevicius L; Nilsson C; Remberger M; Aschan J; Concha H; Gaughan U; Hassan M
Exp Hematol; 2006 Jan; 34(1):115-21. PubMed ID: 16413398
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Galaup A; Paci A
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Casper J; Knauf W; Blau I; Ruutu T; Volin L; Wandt H; Schafer-Eckart K; Holowiecki J; Giebel S; Aschan J; Zander A; Kroger N; Doelken G; Freund M
Ann Hematol; 2004; 83 Suppl 1():S70-1. PubMed ID: 15124679
[TBL] [Abstract][Full Text] [Related]
12. Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2004 Jan; 33(2):153-9. PubMed ID: 14661037
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of treosulfan on prostate cancer cell lines.
Feyerabend S; Feil G; Krug J; Kassen A; Stenzl A
Anticancer Res; 2007; 27(4B):2403-8. PubMed ID: 17695531
[TBL] [Abstract][Full Text] [Related]
14. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Danylesko I; Shimoni A; Nagler A
Bone Marrow Transplant; 2012 Jan; 47(1):5-14. PubMed ID: 21478921
[TBL] [Abstract][Full Text] [Related]
15. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients.
Meinhardt G; Dayyani F; Jahrsdörfer B; Baumgart J; Emmerich B; Schmidmaier R
Br J Haematol; 2003 Sep; 122(6):892-9. PubMed ID: 12956758
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Wachowiak J; Sykora KW; Cornish J; Chybicka A; Kowalczyk JR; Gorczyńska E; Choma M; Grund G; Peters C;
Bone Marrow Transplant; 2011 Dec; 46(12):1510-8. PubMed ID: 21297673
[TBL] [Abstract][Full Text] [Related]
19. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
Köpf-Maier P
In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan induces distinctive gonadal toxicity compared with busulfan.
Levi M; Stemmer SM; Stein J; Shalgi R; Ben-Aharon I
Oncotarget; 2018 Apr; 9(27):19317-19327. PubMed ID: 29721205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
